Evidence map›Paper›PMID 33478308›Full record

SynthesisThe Journal of international medical research2021

Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis.

Yonghui Chen, Hongrui Pan, Guangze Luo, Peng Li, Xiangchen Dai

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Article
  5. Successful baroreflex activation therapy in a case of therapy-resistant renovascular hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yonghui ChenVascular Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.
Hongrui PanVascular Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.
Guangze LuoVascular Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.ORCID https://orcid.org/0000-0002-2984-9281
Peng LiVascular Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.
Xiangchen DaiVascular Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.ORCID https://orcid.org/0000-0001-9074-6452
Tianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFor patients with atherosclerotic renal artery stenosis (ARAS), the role of percutaneous transluminal renal angioplasty (PTRA) remains inconclusive. This study aimed to comparatively evaluate the benefits of best medical therapy (BMT) plus PTRA and BMT alone in treating ARAS.

methodsWe performed a systematic review and meta-analysis, and searched for all randomized, controlled trials that reported patients with ARAS. The effectiveness and safety in the BMT plus PTRA and BMT alone groups were estimated, taking into account hypertension, stroke, renal events, cardiac events, and mortality.

resultsNine randomized, controlled trials involving 2309 patients were included. In the BMT plus PTRA group, the incidence of refractory hypertension was significantly lower compared with that in the BMT alone group (odds ratio 0.09; 95% confidence interval 0.01, 0.70). However, there were no significant differences in the rates of stroke, renal events, cardiac events, cardiac mortality, and all-cause mortality between the two groups.

conclusionsPTRA plus BMT improves blood pressure in patients with ARAS, but there is insufficient evidence for this therapy in improving stroke, renal events, cardiac events, and cardiac and all-cause mortality.

Indexed as

AtherosclerosisRenal Artery ObstructionAngioplastyHumansKidneyRandomized Controlled Trials as TopicRenal Arteryall-cause mortalityAtherosclerotic renal artery stenosisbest medical therapycardiac mortalitypercutaneous transluminal renal angioplastyrenal eventstroke

Identifiers

PMID33478308
PMCPMC7841243
OpenAlexW3125881114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.